Hongyu Li

Title: Innovations of Hongyu Li in Alzheimer's Disease Treatment

Introduction

Hongyu Li is a notable inventor based in Gansu, China. He has made significant contributions to the field of medicine, particularly in the treatment of Alzheimer's disease. With a total of two patents to his name, his work focuses on innovative solutions that address critical health issues.

Latest Patents

One of Hongyu Li's latest patents is a fusion protein for alpha-melanocyte stimulating hormone and its preparation method and use. This fusion protein contains a protein transduction domain (PTD), human serum albumin (HSA), and alpha-melanocyte stimulating hormone (α-MSH). The patent discloses methods for preparing this fusion protein and its application in inhibiting or treating central nervous system inflammations. Another significant patent involves the use of a Chinese medicine composition and Dianxianning in the preparation of a medicament for preventing or treating Alzheimer's disease. Experimental results indicate that this composition has a significant inhibiting effect on the palsy phenotype in animal models of Alzheimer's disease, suggesting its potential as a preventive or therapeutic agent.

Career Highlights

Hongyu Li is affiliated with Lanzhou University, where he continues to engage in research and development. His work is characterized by a commitment to advancing medical science and improving patient outcomes through innovative treatments.

Collaborations

He collaborates with esteemed colleagues, including Dejuan Zhi and Yang Li, who contribute to his research endeavors. Their combined expertise enhances the potential impact of their work in the medical field.

Conclusion

Hongyu Li's innovative patents and research efforts represent a significant advancement in the treatment of Alzheimer's disease. His contributions are paving the way for new therapeutic options that could improve the quality of life for many individuals affected by this condition.